• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Eledon Pharmaceuticals Inc (NQ: ELDN )

    2.480 +0.010 (+0.40%)
    Streaming Delayed Price Updated: 3:45 PM EDT, Jul 9, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Eledon Pharmaceuticals Inc

    < Previous 1 2 Next >
    Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    Eledon Pharmaceuticals Inc. (NASDAQ: ELDN) Leading the Way in Monday Trading Based on Percentage Gain
    Via Investor Brand Network
    Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    Eledon Pharmaceuticals to Present Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Society of Nephrology Kidney Week 2023 Annual Meeting
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    Eledon Pharmaceuticals Appoints Kidney Transplant Specialist Dr. Allan Douglas Kirk to Board of Directors
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    Eledon Pharmaceuticals Announces Use of Tegoprubart anti-CD40L Antibody in Second-ever Transplant of Genetically Modified Heart from a Pig to a Human
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    Eledon Pharmaceuticals to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    Eledon Pharmaceuticals Announces Publication of Data Showing Treatment with Tegoprubart Promotes Kidney and Islet Allograft Survival and Function in Nonhuman Primates
    Results from study published in Science Translational Medicine support further clinical development of tegoprubart (AT-1501) as a potential agent to promote kidney allograft survival and function in... 
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    Eledon Pharmaceuticals Announces First Participant Dosed in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Rejection in Kidney Transplantation
    Trial to assess potential of tegoprubart-based immunosuppression to improve graft function compared to tacrolimus-based immunosuppression 
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    Eledon Pharmaceuticals Announces Dosing of 10th Patient in Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    Eledon Pharmaceuticals Reports Second Quarter 2023 Operating and Financial Results
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    Eledon Pharmaceuticals to Present at Jefferies Healthcare Conference
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    Eledon Pharmaceuticals Inc. (NASDAQ: ELDN) Leading the Way in Wednesday Trading Based on Percentage Gain
    Via Investor Brand Network
    Eledon Pharmaceuticals Reports First Quarter 2023 Operating and Financial Results
    From Eledon Pharmaceuticals, Inc.
    Via GlobeNewswire
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.